Restoration of primary cilia in obese adipose-derived mesenchymal stem cells by inhibiting Aurora A or extracellular signal-regulated kinase.
Adipose-derived mesenchymal stem cells
Aurora A
Extracellular signal-regulated kinase 1/2
Glycogen synthase kinase 3 beta
Obesity
Primary cilium
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
14 08 2019
14 08 2019
Historique:
received:
09
04
2019
accepted:
05
08
2019
revised:
23
07
2019
entrez:
16
8
2019
pubmed:
16
8
2019
medline:
14
7
2020
Statut:
epublish
Résumé
Obesity impairs a variety of cell types including adipose-derived mesenchymal stem cells (ASCs). ASCs are indispensable for tissue homeostasis/repair, immunomodulation, and cell renewal. It has been demonstrated that obese ASCs are defective in differentiation, motility, immunomodulation, and replication. We have recently reported that some of these defects are linked to impaired primary cilia, which are unable to properly convey and coordinate a variety of signaling pathways. We hypothesized that the rescue of the primary cilium in obese ASCs would restore their functional properties. Obese ASCs derived from subcutaneous and visceral adipose tissues were treated with a specific inhibitor against Aurora A or with an inhibitor against extracellular signal-regulated kinase 1/2 (Erk1/2). Multiple molecular and cellular assays were performed to analyze the altered functionalities and their involved pathways. The treatment with low doses of these inhibitors extended the length of the primary cilium, restored the invasion and migration potential, and improved the differentiation capacity of obese ASCs. Associated with enhanced differentiation ability, the cells displayed an increased expression of self-renewal/stemness-related genes like SOX2, OCT4, and NANOG, mediated by reduced active glycogen synthase kinase 3 β (GSK3β). This work describes a novel phenomenon whereby the primary cilium of obese ASCs is rescuable by the low-dose inhibition of Aurora A or Erk1/2, restoring functional ASCs with increased stemness. These cells might be able to improve tissue homeostasis in obese patients and thereby ameliorate obesity-associated diseases. Additionally, these functionally restored obese ASCs could be useful for novel autologous mesenchymal stem cell-based therapies.
Sections du résumé
BACKGROUND
Obesity impairs a variety of cell types including adipose-derived mesenchymal stem cells (ASCs). ASCs are indispensable for tissue homeostasis/repair, immunomodulation, and cell renewal. It has been demonstrated that obese ASCs are defective in differentiation, motility, immunomodulation, and replication. We have recently reported that some of these defects are linked to impaired primary cilia, which are unable to properly convey and coordinate a variety of signaling pathways. We hypothesized that the rescue of the primary cilium in obese ASCs would restore their functional properties.
METHODS
Obese ASCs derived from subcutaneous and visceral adipose tissues were treated with a specific inhibitor against Aurora A or with an inhibitor against extracellular signal-regulated kinase 1/2 (Erk1/2). Multiple molecular and cellular assays were performed to analyze the altered functionalities and their involved pathways.
RESULTS
The treatment with low doses of these inhibitors extended the length of the primary cilium, restored the invasion and migration potential, and improved the differentiation capacity of obese ASCs. Associated with enhanced differentiation ability, the cells displayed an increased expression of self-renewal/stemness-related genes like SOX2, OCT4, and NANOG, mediated by reduced active glycogen synthase kinase 3 β (GSK3β).
CONCLUSION
This work describes a novel phenomenon whereby the primary cilium of obese ASCs is rescuable by the low-dose inhibition of Aurora A or Erk1/2, restoring functional ASCs with increased stemness. These cells might be able to improve tissue homeostasis in obese patients and thereby ameliorate obesity-associated diseases. Additionally, these functionally restored obese ASCs could be useful for novel autologous mesenchymal stem cell-based therapies.
Identifiants
pubmed: 31412932
doi: 10.1186/s13287-019-1373-z
pii: 10.1186/s13287-019-1373-z
pmc: PMC6694567
doi:
Substances chimiques
AURKA protein, human
EC 2.7.11.1
Aurora Kinase A
EC 2.7.11.1
Extracellular Signal-Regulated MAP Kinases
EC 2.7.11.24
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
255Références
Oncotarget. 2016 Dec 20;7(51):84271-84285
pubmed: 27713178
Med Clin North Am. 2018 Jan;102(1):1-11
pubmed: 29156178
Circ Res. 2007 May 11;100(9):1249-60
pubmed: 17495232
Stem Cell Reports. 2017 Jun 6;8(6):1457-1464
pubmed: 28591647
Dev Cell. 2016 Aug 22;38(4):333-44
pubmed: 27554855
Biochem Biophys Res Commun. 2015 Feb 27;458(1):117-22
pubmed: 25637533
Cell Cycle. 2016;15(6):827-39
pubmed: 27029530
Circulation. 2016 Feb 16;133(7):639-49
pubmed: 26746176
J Thorac Dis. 2018 Sep;10(9):5476-5488
pubmed: 30416797
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5349-54
pubmed: 24706870
Stem Cells. 2016 Jun;34(6):1445-54
pubmed: 26866419
Curr Opin Clin Nutr Metab Care. 2010 Jul;13(4):371-6
pubmed: 20531178
Nat Rev Mol Cell Biol. 2013 Jul;14(7):416-29
pubmed: 23719536
Pharmacol Ther. 2015 Apr;148:114-31
pubmed: 25435019
Stem Cell Reports. 2018 Jul 10;11(1):58-69
pubmed: 29779897
Nature. 2006 Dec 14;444(7121):875-80
pubmed: 17167476
Annu Rev Immunol. 2011;29:415-45
pubmed: 21219177
Cell Cycle. 2015;14(23):3755-67
pubmed: 26148251
Oncotarget. 2016 Aug 2;7(31):50215-50228
pubmed: 27384476
Cardiovasc Res. 2017 Jul 1;113(9):1064-1073
pubmed: 28498891
PLoS One. 2013 May 17;8(5):e62554
pubmed: 23690943
PLoS One. 2012;7(6):e38838
pubmed: 22701722
Cancer Lett. 2014 Apr 1;345(1):100-5
pubmed: 24333718
J Biol Chem. 2003 Feb 14;278(7):5242-9
pubmed: 12456685
Mol Cells. 2018 Jun;41(6):575-581
pubmed: 29890823
Obes Rev. 2018 Oct;19(10):1317-1328
pubmed: 30015415
Nat Rev Dis Primers. 2017 Jun 15;3:17034
pubmed: 28617414
Organogenesis. 2014 Jan 1;10(1):62-8
pubmed: 24743231
Stem Cell Res Ther. 2015 Dec 01;6:234
pubmed: 26620426
Cell Commun Signal. 2018 Dec 5;16(1):96
pubmed: 30518391
EMBO Rep. 2018 Nov;19(11):
pubmed: 30348893
Differentiation. 2007 Apr;75(4):299-307
pubmed: 17286604
Nat Commun. 2012;3:1085
pubmed: 23011139
Stem Cells Transl Med. 2017 Feb;6(2):539-565
pubmed: 28191766
Cell. 2017 Jan 12;168(1-2):264-279.e15
pubmed: 28086093
Adv Biol Regul. 2017 Aug;65:5-15
pubmed: 28712664
Front Physiol. 2018 Dec 19;9:1838
pubmed: 30618843
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
Stem Cell Reports. 2018 Feb 13;10(2):583-599
pubmed: 29396182
Obes Rev. 2010 Jan;11(1):11-8
pubmed: 19656312
Trends Cell Biol. 2017 Feb;27(2):126-140
pubmed: 27634431
Cancers (Basel). 2014 Mar 26;6(2):741-55
pubmed: 24675570
Nat Cell Biol. 2014 Jul;16(7):663-72
pubmed: 24952464
Cell Rep. 2018 Jun 5;23(10):3042-3055
pubmed: 29874589
Stem Cells. 2015 Jun;33(6):1952-61
pubmed: 25693948
EMBO J. 2012 May 18;31(14):3104-17
pubmed: 22609948
J Cell Biol. 2014 Mar 17;204(6):1063-74
pubmed: 24616223
Oncogene. 2017 Apr;36(15):2146-2159
pubmed: 27721410
Stem Cells. 2016 Oct;34(10):2559-2573
pubmed: 27352919
Nat Rev Genet. 2010 May;11(5):331-44
pubmed: 20395968
Nat Cell Biol. 2016 Jun 28;18(7):711-7
pubmed: 27350441
PLoS Biol. 2008 Oct 21;6(10):e253
pubmed: 18942890
Oncogene. 2017 Jun 8;36(23):3322-3333
pubmed: 28068326
Nat Rev Cancer. 2011 Nov 24;11(12):886-95
pubmed: 22113164
Nat Rev Cancer. 2018 Aug;18(8):511-524
pubmed: 29802351
Oncotarget. 2015 Oct 27;6(33):34475-93
pubmed: 26439686
Clin Cancer Res. 2019 Jul 1;25(13):4179-4193
pubmed: 30867219
Stem Cells. 2011 Mar;29(3):404-11
pubmed: 21425404
Elife. 2016 Mar 22;5:
pubmed: 27003818
J Recept Signal Transduct Res. 2015;35(6):600-4
pubmed: 26096166
Cell Stem Cell. 2012 Mar 2;10(3):312-26
pubmed: 22385658
Obes Rev. 2018 Jul;19(7):888-904
pubmed: 29521029